IHS Chemical Week

People & Business :: M&A

Bayer bids to acquire Norwegian pharma company Algeta

1:26 PM MST | November 26, 2013 | Natasha Alperowicz

The board of directors of Algeta (Oslo) today announced that it has received a preliminary acquisition proposal from Bayer. Bayer has offered to pay 336 Norwegian Krone per Algeta share, valuing the bid at $2.4 billion. Algeta is Bayer’s partner in a new prostate cancer treatment. Algeta says discussions are at an early stage and further announcements may be made in due course.   Bayer and Algeta are partners in Xofigo, which was approved by the US FDA on 15 May 2013 for the treatment of patients with castration-resistant prostate cancer, symptomatic...

This information is only available to Chemical Week subscribers.


Forgot your user ID or password?
Click here to have it sent to you.

Not an IHS Chemical Week subscriber yet?

Here's why you should be:

  • 31 issues of Chemical Week magazine a year in print or digital format
  • Real time news and analysis on chemweek.com 
  • 20+ years of online archives
  • Topical e-newsletters that capture the most impactful events
  • Special issues with a regional or company focus
  • Global Outlook issue

Subscribe now


contact us | about us | privacy policy | sitemap

ihsCopyright © IHS, Inc.All rights reserved.Reproduction in whole or in part without permission is prohibited.

North Asia Russia Southeast Asia China India/Pakistan Middle East Eastern Europe Western Europe Central America Canada USA Australia/New Zealand South America Africa